Clinical trials: Elranatamab, active
Multiple Myeloma
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or…
- Trial name
- NCT06121843
- Testing
- BMS-986393, Alnuctamab, Mezigdomide
- Where
- 19 sites in United States, Canada
- Volunteers
- 187 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Smoldering Multiple Myeloma
Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
This is a multicenter, single arm, open-label, Phase 2 study in high risk smoldering myeloma patients. The primary objective is to determine the efficacy of Elranatamab in patients with previously untreated high-risk SMM.
- Trial name
- ERASMM (NCT06183489)
- Testing
- Elranatamab
- Where
- 18 sites in France, Italy and 2 more
- Volunteers
- 50 people
- Sponsor
- European Myeloma Network B.V.
Multiple Myeloma
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab…
- Trial name
- MAGNETISMM-5 (NCT05020236)
- Testing
- Elranatamab, Daratumumab, Pomalidomide
- Where
- 237 sites in United States, Argentina and 24 more
- Volunteers
- 893 people
- Sponsor
- Pfizer
TCE-RRMM
ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab
This registry study will provide valuable evidence to assess and validate its effectiveness in the Chinese MM population, refine clinical application strategies, and support the optimization of BCMA BsAbs use in MM treatment in…
- Trial name
- ASPIRE (NCT07320326)
- Testing
- Elranatamab
- Where
- China
- Volunteers
- 159 people
- Sponsor
- Peking University People's Hospital
Relapsed Refractory Multiple Myeloma (RRMM)
Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
The goal of this clinical trial is to find out how well a combination of two medicines (mezigdomide and elranatamab) works in treating patients with refractory/relapsed multiple myeloma.
- Trial name
- MELT-MM (NCT06645678)
- Testing
- Elranatamab, Mezigdomide, Dexamethasone
- Where
- 7 sites in Singapore, South Korea
- Volunteers
- 75 people
- Sponsor
- YOUNGIL KOH
Multiple Myeloma
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
The main purpose of the study is to evaluate the safety and tolerability of the combination of elranatamab and carfilzomib and dexamethasone or elranatamab and maplirpacept. There are 2 parts to this study.
- Trial name
- MagnetisMM-20 (NCT05675449)
- Testing
- Elranatamab, Carfilzomib, Maplirpacept
- Where
- 36 sites in United States, Israel
- Volunteers
- 59 people
- Sponsor
- Pfizer
Multiple Myeloma in Relapse
Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes
The goal of this phase II, open-label, single-arm, multicenter study is to evaluate i) the efficacy and ii) safety of elranatamab monotherapy at the dose of 76 mg subcutaneously in participants with RRMM after at least one or two…
- Trial name
- NCT06282978
- Testing
- Elranatamab (PF-06863135)
- Where
- 13 sites in Spain
- Volunteers
- 50 people
- Sponsor
- PETHEMA Foundation
Hemophilia A With Inhibitors
A Study of Elranatamab for Inhibitor Eradication in Patients With Hemophilia A
This is a prospective, single-arm, open-label, exploratory clinical study designed to evaluate the safety and efficacy of Elranatamab for inhibitor eradication in adults with moderate-to-severe hemophilia A with inhibitors.
- Trial name
- NCT07788469
- Testing
- Elranatamab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
This is an open-label, multi-site, Phase II randomized trial with response-adaptive design for newly diagnosed multiple myeloma (NDMM) participants who have had prior induction therapy.
- Trial name
- FASTER (NCT06974786)
- Testing
- Elranatamab, Daratumumab, Lenalidomide
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- SCRI Development Innovations, LLC
Relapsed Refractory Multiple Myeloma (RRMM)
Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy
This is an open-label, single arm, multicenter study to evaluate the efficacy of letermovir in the prevention of clinically significant CMV infection in adult, CMV-seropositive relapsed/refractory MM patients undergoing BsAbs…
- Trial name
- OPTIMUS-EL (NCT06920251)
- Testing
- Letermovir
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Seoul National University Hospital
Refractory Multiple Myeloma, Relapse Multiple Myeloma
Elranatamab in R/R Multiple Myeloma
This research is being done to see if the study drug, elranatamab, reduces the risk of disease progression (worsening disease) after idecabtagene vicleucel in relapsed refractory multiple myeloma.
- Conditions
- Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma
- Trial name
- NCT06138275
- Testing
- Elranatamab
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Massachusetts General Hospital
Multiple Myeloma
ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)
The purpose of this study is to determine the effects that Elranatamab in combination with Lenalidomide and Dexamethasone has on participants that have been newly diagnosed with Multiple Myeloma.
- Trial name
- NCT06997081
- Testing
- Lenalidomide, Dexamethasone, Elranatamab
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- University of Miami
Amyloid Light-chain Amyloidosis
Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis
This research study is for people who have newly diagnosed with AL (light chain) amyloidosis and have not yet received any treatment for this condition.
- Trial name
- NCT07524634
- Testing
- BCMA bispecific
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Case Comprehensive Cancer Center
Multiple Myeloma
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.
- Trial name
- MagnetisMM-6 (NCT05623020)
- Testing
- Elranatamab, Daratumumab, Lenalidomide
- Where
- 180 sites in United States, Argentina and 23 more
- Volunteers
- 1,060 people
- Sponsor
- Pfizer
Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
The goal of this clinical trial is to learn if the drug combination Elranatamab plus Mezigdomide plus Dexametahsone works to cure patients with relapsed/refractory multiple myeloma.
- Trial name
- GEM-MeziDEL (NCT07901868)
- Testing
- Dexamethasone, Mezigdomide, Elranatamab
- Where
- 20 sites in Spain
- Volunteers
- 60 people
- Sponsor
- PETHEMA Foundation
Multiple Mieloma
Infection Surveillance of R/R Multiple Myeloma Patients Treated With Elranatamab as Clinical Practice in Italy
The primary objective of this study is to measure the infection rate and presentation pattern in first 12 months of therapy with elranatamab as standard clinical practice in adult patients with Relapsed/Refractory Multiple…
- Trial name
- RISE (NCT07564128)
- Volunteers
- 50 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Multiple Myeloma
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing…
- Trial name
- MagnetisMM-7 (NCT05317416)
- Testing
- Elranatamab, Lenalidomide
- Where
- 209 sites in United States, Australia and 25 more
- Volunteers
- 854 people
- Sponsor
- Pfizer
Refractory Multiple Myeloma
Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
A phase II study of single agent elranatamab in patients with relapsed and/or refractory multiple myeloma (MM) who have previously received at least three classes of therapeutic agents and are refractory to the last line of…
- Trial name
- EMBRACE (NCT06421675)
- Testing
- Elranatamab injection
- Where
- 6 sites in Canada
- Volunteers
- 40 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Multiple Myeloma
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.
- Trial name
- MagnetisMM15 (NCT06057402)
- Testing
- Elranatamab
- Where
- 33 sites in United States, Australia and 5 more
- Volunteers
- 80 people
- Sponsor
- Pfizer
Plasmablastic Lymphoma, HIV
HEME-25 Open-Label Feasibility Study of Elranatamab Utilized as Consolidation in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV
This is a single-arm feasibility trial in which patients with histologically confirmed plasmablastic lymphoma (PBL) with or without HIV, who have achieved a Complete Response or Partial Response after definitive frontline…
- Conditions
- Plasmablastic Lymphoma, HIV, Consolidation
- Trial name
- HEME-25 (NCT07647432)
- Testing
- Elranatamab (Elra)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Illinois Chicago